Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00757341 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00757341 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 6 participants.
The verdict
NCT00757341, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will assess the mass balance, metabolic disposition, and identification of metabolites following single oral administration of \[14C\]-SKI-606 in healthy male subjects.
Interventions
- DRUG SKI-606
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-12 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00757341
The ClinicalTrials.gov registry entry for NCT00757341 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SKI-606 is the first listed.
NCT00757341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00757341 about?
NCT00757341 is a clinical study titled "Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606". This study will assess the mass balance, metabolic disposition, and identification of metabolites following single oral administration of \[14C\]-SKI-606 in healthy male subjects.
What is the current status of trial NCT00757341?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2008-12. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00757341?
The interventions under investigation include: SKI-606 (DRUG).
Who is sponsoring clinical trial NCT00757341?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.